A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study of PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid tumors. The study is to be conducted in two parts: the Dose Escalation Phase and the Dose Confirmation Phase.

Enrollment for dose escalation and dose confirmation is complete.

Key Inclusion Criteria:

• Histologically or cytologically confirmed metastatic or locally advanced, squamous or non-squamous NSCLC (NSCLC). Patients must have received no more than four prior lines of therapy, including a PD-1 / PD-L1-containing therapy and a platinum containing regimen. Patients must have received no more than one taxane containing regimen and no more than one investigational agent;
• Must provide study-related tumor specimens;
• ECOG(PS) 0-1;
• Estimated Life Expectancy > 3 months;
• Adequate bone marrow (BM), renal, hepatic and metabolic function.

Key Exclusion Criteria:

• Concurrent cancer treatment with cytoreductive therapy, radiotherapy, cytokine therapy, cytotoxic agents, targeted small molecule therapy or any investigational anticancer small molecule drugs within 2 weeks prior to the start of study treatment (except 5 weeks from last dose of nitrosourea compound) OR treatment with monoclonal antibodies within 4 weeks prior to the start of study treatment;
• Known symptomatic central nervous system (CNS) metastases requiring steroids.
• Diagnosis of any other malignancy within 2 years prior to enrollment;
• Vaccination within 4 weeks of the first dose of study treatment is prohibited except for administration of inactivated vaccines;
• Current use of immunosuppressive medication at study entry;
• Active or prior autoimmune disease that might deteriorate with receiving an immunostimulatory agent;
• Acute or chronic infections requiring systemic therapy;
• Known history of autoimmune colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis;
• Known intolerance to checkpoint inhibitor therapy, defined by the occurrence of an AE leading to drug discontinuation;
• Participation in other studies involving investigational drug(s) within 28 days prior to study entry and/or during study participation.